Bone Marrow Purging

Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.

Also Known As:

Networked: 109 relevant articles (6 outcomes, 13 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Huang, Hui-Fang: 2 articles (08/2012 - 09/2003)
2.	Dimitriou, H: 2 articles (09/2005 - 05/2000)
3.	Kalmanti, M: 2 articles (09/2005 - 05/2000)
4.	Chen, Wan-Zi: 1 article (08/2012)
5.	Lin, Xiao-Lan: 1 article (08/2012)
6.	Hu, Zhen-Ping: 1 article (09/2007)
7.	Liu, Wen-Li: 1 article (09/2007)
8.	Stuart, Berger: 1 article (09/2007)
9.	Zhang, Yi-Cheng: 1 article (09/2007)
10.	Huang, Weitao: 1 article (11/2005)

Related Diseases

1.	Leukemia 11/01/2005 - "Development of a gene therapy based bone marrow purging system for leukemias." 01/01/2000 - "When these 32Dv-src cells were infected with a TP53-recombinant retrovirus before intravenous injection, we found a decreased mortality and, in those animals that develop leukemia, a drastic reduction of the generalized organ infiltration, suggesting that exogenous TP53 expression might be used for ex vivo bone marrow purging from leukemia cells." 05/01/1987 - "These compounds could potentially be useful in purging bone marrow of leukemic cells in autologous marrow transplantation in acute leukemia. " 09/01/1985 - "This information was useful for determining the optimal conditions for purging bone marrow of leukemia cells for ABMT." 12/01/1994 - "Photodynamic therapy also shows promise in the treatment of a number of nonneoplastic conditions, including psoriasis, macular degeneration of the retina, atherosclerotic plaque and restenosis, bone marrow purging for treatment of leukemias with autologous bone marrow transplantation, inactivation of viruses in blood or blood products, and several autoimmune conditions, including rheumatoid arthritis. "
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/01/2001 - "In order to investigate the effect of autologous dendritic cells (DCs) activating bone marrow cells and purging bone marrow from chronic myelogenous leukemia (CML) patients, DCs were separated by negative selection system of human cells from bone marrow mononuclear cells (BMMNCs) of 2 CML patients in hematological remission and harvested after 3 days of culture in IMDM containing autologous plasma, rhGM-CSF and rhTNFalpha at 37 degrees C, 5% CO(2) humidified atmosphere. " 12/01/2001 - "[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]." 03/01/1995 - "Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia." 01/01/1995 - "Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia." 01/01/1995 - "In patients with chronic myelogenous leukemia (CML), LAK cells can only be used in some patients for purging bone marrow since LAK cells possess no or only limited cytolytic activity against autologous CML tumor cells in most cases. "
3.	Neoplasms (Cancer) 04/01/2003 - "On the other hand, immunological effector cells are capable of purging bone marrow transplants in vitro and of destroying disseminated tumor cells in vivo. " 10/01/1995 - "One potential application of this protector is during bone marrow purging to selectively remove contaminating cancer cells. " 05/01/1992 - "An effective immunomagnetic method for bone marrow purging in T cell malignancies." 01/01/1992 - "Bone marrow purging in patients with refractory cancer." 08/15/1990 - "They appear to be selectively more toxic to cancer cells than to normal cells and thus they are ideal candidates for bone-marrow purging procedures. "
4.	Lymphoma (Lymphomas) 10/01/1996 - "Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells." 07/15/1996 - "Using human c-myc-directed antisense ODNs as a model for the application of this approach to bone marrow purging, selective killing of human lymphoma U937 cells relative to normal human bone marrow cells was shown in cell mixing studies. " 11/01/1991 - "High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging." 06/01/1992 - "Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas." 09/01/1989 - "The efficacy of a novel monosized and magnetizable polymer bead, denoted M-280, in immunomagnetic removal of Rael B-lymphoma cells was compared with that of M-450 beads, previously used in bone marrow purging. "
5.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/01/1997 - "In summary, our results show that this immunomagnetic procedure achieves high levels of target cell depletion and can be safely applied to bone marrow purging in childhood ALL patients." 06/01/1997 - "Immunomagnetic bone marrow purging in children with acute lymphoblastic leukemia." 01/01/1994 - "Bone marrow purging in acute lymphoblastic leukemia: biological and clinical features." 01/01/1994 - "Autologous bone marrow transplantation for acute lymphoblastic leukemia: role of bone marrow purging." 03/01/1991 - "Immunomagnetic bone marrow purging of common acute lymphoblastic leukemia cells: suitability of BioMag particles."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	1-phenyl-3,3-dimethyltriazene (PDT)
3.	Catalytic RNA (Ribozymes)
4.	Complement System Proteins (Complement)
5.	perfosfamide
6.	Polymers
7.	N-methyl-valyl-amiclenomycin (BA 2)
8.	M 280
9.	N-(2-cyanoethylene)urea (BA 1)
10.	Immunotoxins (Immunotoxin)

Related Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
2.	Photochemotherapy (Photodynamic Therapy)
3.	Autologous Transplantation
4.	Therapeutics
5.	Lasers (Laser)